M
0.752
0.03 (4.31%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Milestone Pharmaceuticals Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.8 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.0 |
| 相对估值 | NA |
| 财务健康 | -2.5 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -1.23 |
|
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.71% |
| 机构持股比例 | 22.25% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Pavaki Capital Management Llc | 30 Sep 2026 | 9,337,848 |
| Rvw Wealth, Llc | 30 Sep 2026 | 1,148,260 |
该时间范围内无数据。
该时间范围内无数据。
投资组合